Published in AIDS Res Hum Retroviruses on January 01, 2002
Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France. Clin Exp Immunol (2007) 1.19
The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol (2005) 1.11
Expression of CD134 and CXCR4 mRNA in term placentas from FIV-infected and control cats. Vet Immunol Immunopathol (2008) 0.88
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
HIV vaccine research: the way forward. Science (2008) 3.86
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol (2002) 2.23
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood (2010) 1.72
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood (2002) 1.70
Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr (2002) 1.59
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol (2008) 1.44
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol (2012) 1.44
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 1.41
A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell (2006) 1.38
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol (2006) 1.31
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis (2006) 1.31
CD4 immunophenotyping in HIV infection. Nat Rev Microbiol (2008) 1.27
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol (2009) 1.26
Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology (2008) 1.26
Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. J Virol (2009) 1.24
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis (2004) 1.21
Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol (2011) 1.18
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest (2014) 1.14
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis (2003) 1.11
The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr (2008) 1.10
Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol (2007) 1.09
Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J Leukoc Biol (2010) 1.09
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS (2009) 1.09
A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry B Clin Cytom (2008) 1.06
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res (2012) 1.05
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr (2003) 1.05
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol (2013) 1.04
Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J Virol (2009) 1.03
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS (2004) 1.03
CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology (2003) 1.01
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr (2003) 1.01
Mother-to-child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr (2004) 1.01
Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol (2013) 1.01
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis (2005) 1.00
A proprietary extract from North American ginseng (Panax quinquefolium) enhances IL-2 and IFN-gamma productions in murine spleen cells induced by Con-A. Int Immunopharmacol (2004) 0.99
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions. Retrovirology (2013) 0.99
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis (2012) 0.98
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol (2007) 0.97
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS (2007) 0.96
Infection of placental trophoblasts by Toxoplasma gondii. J Infect Dis (2003) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis (2004) 0.95
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol (2003) 0.95
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS (2007) 0.94
Immunophenotypic alterations in acute and early HIV infection. Clin Immunol (2007) 0.94
Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem Biol (2011) 0.94
Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology (2007) 0.93
The effects of preeclampsia and oxygen environment on endothelial release of matrix metalloproteinase-2. Hypertens Pregnancy (2004) 0.93
Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr (2008) 0.93
Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis (2010) 0.93
GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One (2012) 0.92
Human cytomegalovirus-caused damage to placental trophoblasts mediated by immediate-early gene-induced tumor necrosis factor-alpha. Am J Pathol (2002) 0.92
Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS (2014) 0.92
Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr (2007) 0.91
Epidermal growth factor stimulation of trophoblast differentiation requires MAPK11/14 (p38 MAP kinase) activation. Biol Reprod (2005) 0.91
Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans. AIDS Res Hum Retroviruses (2012) 0.91
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis (2003) 0.90
Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses. Blood (2006) 0.90